Received Aug 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 5g23d | IM / RL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | y009348 | IM / LL |
The patient presented to Clinic on 08/18/2025 at approximately 0800 for routine immunizations. ProQuad was administered in the left thigh and Kinrix in the right thigh. The patient tolerated the injections without complication and departed the clinic at approximately 0910. At 0915, the patient?s father called reporting a new onset rash and cough. He was advised to return to the clinic for further evaluation. Upon arrival, the patient was noted to be in respiratory distress. Dr. and FNP-BC evaluated the patient. Oxygen saturation was 92% on room air. Examination revealed barrel chest, retracted breathing, and a splotchy erythematous rash across the torso. The patient also demonstrated tachypnea and vomiting. At 0950, Dr. administered Epinephrine 0.15 mg IM to the left thigh, followed by Decadron 4 mg/mL and Diphenhydramine 50 mg/mL. The patient showed an adequate response to treatment with improvement in oxygen saturation to 98% on room air and a pulse of 132 bpm. An ambulance was dispatched for transfer to Emergency Department for continued monitoring. The patient arrived at approximately 1043. He remained stable throughout observation and was prescribed Prednisolone 15 mg/5 mL for home use. The patient was discharged in stable condition at 1252.
None
None
None
None
N/a